News BMS signs $15.2bn R&D alliance with China's Hengrui Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.
R&D Sponsored 12 Questions with Matthew Goodman LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.
News 'Seismic shift' as obesity overtakes cancer for R&D returns For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.
Digital From static documents to strategic capability: The case for ... Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.
News Amazon launches its AI drug discovery platform Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.
R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.